Medicine and Dentistry
Heart Failure
100%
3 Hydroxybutyric Acid
44%
Hemodynamic
44%
Ketone Bodies
43%
Heart Output
38%
Positron Emission Tomography
33%
Placebo
30%
Glucose Uptake
26%
Heart Left Ventricle Ejection Fraction
26%
Infusion
22%
Blood Flow
22%
Heart Function
20%
Maturity Onset Diabetes of the Young
20%
Echocardiography
19%
Heart Muscle Blood Flow
17%
Cardiovascular Effect
17%
Patient with Type 2 Diabetes
17%
Revascularization
16%
Liraglutide
16%
Coronary Artery Disease
15%
Heart Failure with Reduced Ejection Fraction
14%
Conditioning
14%
Heart Muscle Ischemia
13%
Oxygen 15
13%
Fatty Acid
13%
Diabetes
12%
Heart Muscle Oxygen Consumption
11%
Out of Hospital Cardiac Arrest
11%
Pulmonary Hypertension
11%
Cardiogenic Shock
11%
Atrial Fibrillation
11%
Targeted Temperature Management
11%
Aortic Valve Stenosis
11%
Heart Transplantation
11%
Regional Perfusion
11%
Cardiovascular System
10%
Carbon 11
9%
Ejection Fraction
9%
Heart Preload
8%
Disease
8%
Sinus Rhythm
8%
Fluorodeoxyglucose F 18
8%
Contractile Function
7%
Heart Left Ventricle Function
7%
Coronary Circulation
7%
Heart Muscle Contractility
7%
Pulmonary Artery Occlusion Pressure
7%
Glucagon Like Peptide 1
7%
Positron Emission Tomography-Computed Tomography
7%
Heart Muscle Metabolism
6%
Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure
76%
3 Hydroxybutyric Acid
37%
Ketone Bodies
36%
Placebo
33%
Metoprolol
22%
Hypertrophic Obstructive Cardiomyopathy
16%
Liraglutide
16%
Coronary Artery Disease
16%
Non Insulin Dependent Diabetes Mellitus
13%
Pulmonary Hypertension
11%
Cardiogenic Shock
11%
Heart Muscle Ischemia
10%
Disease
9%
All Cause Mortality
9%
Heart Failure with Reduced Ejection Fraction
8%
Carbon 11
7%
Heart Left Ventricle Failure
6%
Cardiomyopathy
6%
Fatty Acid
6%
Natriuretic Factor
6%
Combination Therapy
6%
Glucagon Like Peptide 1 Receptor Agonist
6%
Inflammation
6%
Brain Natriuretic Peptide
5%
Aortic Valve Stenosis
5%
Tricuspid Valve Regurgitation
5%
Adverse Event
5%
Receptor
5%
Erythromycin Ethylsuccinate
5%
Perilipin
5%
Nicotinic Acid
5%
Lipopolysaccharide
5%
Out of Hospital Cardiac Arrest
5%
Beta Adrenergic Receptor Blocking Agent
5%
Heart Ventricle Remodeling
5%
Pig
5%
Butyrate
5%
Inotropic Agent
5%
Short Chain Fatty Acid
5%
Transthyretin
5%
Amyloidosis
5%
Amyloid
5%
Heart Failure with Preserved Ejection Fraction
5%
Non Insulin Dependent Diabetes Mellitus
5%
Keyphrases
Cardiac Output
9%
Coronary Artery Disease
8%
Heart Failure
6%
Vasorelaxation
6%
3-hydroxybutyrate
6%
Positron Emission Tomography
6%
Left Ventricular Ejection Fraction
6%
Ketone Bodies
6%
Chronic Heart Failure
6%
Glucagon-like
6%
Cardiovascular Effects
6%
Liraglutide
5%
Heart Failure Patients
5%
Metoprolol
5%
Myocardial Oxygen Consumption
5%
Transthyretin Amyloid Cardiomyopathy
5%
Oxygen Uptake Rate
5%
Inotropic Agents
5%
All-cause Mortality
5%
Strong Predictor
5%
Heart Rate Increase
5%
Myocardial Function
5%
Test-retest Repeatability
5%
Wild-type Transthyretin Amyloid
5%
Mitochondrial Oxidative Capacity
5%
Without Diabetes
5%
Newly Diagnosed
5%
Multimodality Approach
5%
Oxidation Efficiency
5%
Myocardial Oxidative Metabolism
5%
Myocardial Fatty Acid Oxidation
5%
Denmark
5%
Sodium-glucose Cotransporter
5%
15O-water
5%
Early Revascularization
5%
Extravascular Lung Water
5%
Cardioprotection
5%
Butyrate
5%
Short-chain Fatty Acids
5%
Vasodilator
5%
Atrial Fibrillation
5%
Myocardial Perfusion Imaging
5%
15O-H2O
5%
Hypothermic Oxygenated Machine Perfusion
5%
Direct Procurement
5%
β-hydroxybutyrate
5%
Heart Failure with Preserved Ejection Fraction (HFpEF)
5%
Randomized Crossover Trial
5%
Type 2 Diabetic Patients
5%
Ketone Ester
5%
